Showing 2091-2100 of 5623 results for "".
- Nanoscope Announces 3-Year Vision Improvements from REMAIN Study of MCO-010 in RPhttps://modernod.com/news/nanoscope-announces-3-year-vision-improvements-from-remain-study-of-mco-010-in-retinitis-pigmentosa/2484207/Nanoscope Therapeutics announced 3-year follow-up data from the REMAIN study, the long-term extension of its pivotal phase 2b/3 RESTORE trial evaluating MCO-010, the company’s proprietary optogenetic therapy for retinitis pigmentosa (RP).
- Lumenis Launches Digital Duet 2.0 SLT+YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-20-sltyag-platform/2484200/Lumenis has unveiled Digital Duet 2.0, the latest evolution of its digital SLT+YAG platform for glaucoma and posterior capsulotomy treatment. The new system combines advanced imaging, seamless connectivity, and an enhanced user experience.
- FDA Selects Dompé for National Priority Voucher Program to Accelerate Development of Novel Intranasal Therapyhttps://modernod.com/news/fda-selects-dompe-for-national-priority-voucher-program-to-accelerate-development-of-novel-intranasal-therapy/2484190/Dompé announced its selection by the FDA to participate in the Commissioner’s National Priority Voucher (CNPV) program. Through this designation, Dompé has been awarded a voucher granting a signific
- Topcon Healthcare Signs Definitive Agreement to Acquire Toku Inc.https://modernod.com/news/topcon-healthcare-signs-definitive-agreement-to-acquire-toku-inc/2484189/Topcon Healthcare announced it has signed a definitive agreement to acquire Toku, Inc., a San Diego-based artificial intelligence (AI) health technology company. Financial terms of the deal were not disclosed.
- OcuSciences Secures CE Mark for OcuMet Beacon, Expands European Deploymenthttps://modernod.com/news/ocusciences-secures-eu-ce-clearance-for-ocumet-beacon-expands-european-deployment/2484181/OcuSciences has received CE Mark clearance for its OcuMet Beacon, a diagnostic instrument designed to enhance clinicians’ ability to assess eye health and detect retinal disorders. The CE mark signifies that the OcuMet Beacon meets the health, safet
- Lovell and DefEYE Partner to Expand Access to Biovance Ocular Biologics Across Federal Healthcare Systemshttps://modernod.com/news/lovell-government-services-and-defeye-partner-to-expand-access-to-biovance-ocular-biologics-across-federal-healthcare-systems/2484164/Lovell Government Services and DefEYE, the provider of Biovance decellularized basement membranes for ocular use, announced a partnership to serve federal healthcare systems, including the Veterans Health Administration, the Department of Defense Military
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Modelhttps://modernod.com/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/2484162/NurExone Biologic announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study, conducted in collaboration
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- Kala Halts Development of Investigational PCED Eye Drop After Phase 2b Trial Fails to Meet Endpointshttps://modernod.com/news/kala-halts-development-of-investigational-pced-eye-drop-after-phase-2b-trial-fails-to-meet-endpoints/2484150/Kala Bio said it is ceasing development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform after its phase 2b trial evaluating KPI-012 in persistent corneal epithelial defect (PCED) did not meet its primary or secondary efficacy endpoints.
- Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Dealhttps://modernod.com/news/formycon-expands-european-footprint-for-aflibercept-biosimilar-fyb203-with-horus-pharma-deal/2484146/Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to